Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 18/20 | 1.00 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18189772 | 0.86 | GRIA1 (1.00) | GRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL18189874 | 0.83 | GRIA1 (1.00) | GRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL18189849 | 0.82 | GRIA1 (1.00) | GRIA1CACNG8PDE3BPDE3ACDK2 | |
| SCHEMBL18189800 | 0.81 | GRIA1 (1.00) | GRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL18190040 | 0.75 | GRIA1 (1.00) | GRIA1CACNG8 | |
| SCHEMBL18189827 | 0.69 | GRIA1 (0.51) | GRIA1 | |
| SCHEMBL18189834 | 0.68 | GRIA1 (1.00) | GRIA1 | |
| SCHEMBL18198751 | 0.67 | GRIA1 (0.83) | GRIA1 | |
| SCHEMBL18190064 | 0.66 | GRIA1 (1.00) | GRIA1 | |
| SCHEMBL20086258 | 0.66 | GRIA1 (0.49) | GRIA1CACNG8PDE3BPDE3ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-24 | — | — | US | claimed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | claimed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | claimed |
| EP-3288945-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | claimed |
| WO-2016176457-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | claimed |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-24 | — | — | US | disclosed |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-24 | — | — | US | disclosed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3288945-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176457-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN1, GRIN3A | GRIA1 33/4885CACNG8 228/4885PDE3B 1212/4885 |
| US-10513523-B2 | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators | GRIK5, GRIN1, GRIN3A | GRIA1 33/4885CACNG8 228/4885PDE3B 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.